文献速递胸部肿瘤消化系统肿瘤妇科肿瘤

CH5126766/VS-6766间歇给药方案在RAS/RAF突变实体瘤及多发性骨髓瘤中的1期研究

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
PubMed 文献 · Lancet Oncol · 2020-10-28

这项单中心、开放标签、1期剂量递增及篮式剂量扩展研究评估了MEK-pan-RAF抑制剂CH5126766间歇给药方案的安全性、耐受性和抗肿瘤活性。

要点

  • 常见3-4级治疗相关不良事件为皮疹19%、CPK升高11%、低白蛋白血症11%、乏力7%

核心结论

  • 高度间歇给药方案的RAF-MEK抑制剂在多种RAS-RAF-MEK通路突变癌症中具有抗肿瘤活性且可耐受,值得进一步评估单药及联合方案。

研究设计与样本

  • 单中心、开放标签、1期剂量递增及篮式剂量扩展研究,在英国Royal Marsden NHS Foundation Trust开展。
  • 2013年6月5日至2019年1月10日入组58例合格患者:剂量递增队列29例实体瘤,篮式扩展队列29例实体瘤或多发性骨髓瘤。
  • 篮式扩展在生物标志物选择的患者中评估推荐2期剂量的抗肿瘤活性。
  • 主要终点为推荐2期剂量(不超过1/6患者出现治疗相关剂量限制性毒性)及各方案安全性和毒性特征;关键次要终点为扩展期研究者评估的缓解率。

主要发现

  • 最常见3-4级治疗相关不良事件为皮疹11例(19%)、CPK升高6例(11%)、低白蛋白血症6例(11%)、乏力4例(7%)。
  • 5例(9%)患者发生严重治疗相关不良事件,无治疗相关死亡。
  • 试验期间57例患者中8例(14%)因疾病进展死亡。

关键数值与推荐

  • 剂量限制性毒性判定标准:在推荐2期剂量下不超过1/6患者出现治疗相关剂量限制性毒性。
  • 篮式扩展队列包括12例非小细胞肺癌、5例妇科恶性肿瘤、4例结直肠癌、1例黑色素瘤和7例多发性骨髓瘤。

临床怎么用

  • 治疗期间需重点监测皮疹、CPK升高、低白蛋白血症和乏力等毒性,并依据预设毒性进行剂量调整。
  • 该方案作为单药或联合 regimen 值得进一步临床评估。

局限性

  • 篮式扩展队列为生物标志物选择患者,各瘤种例数少,缓解率需更大样本验证。
  • 剂量递增阶段仅纳入实体瘤患者,多发性骨髓瘤仅进入篮式扩展阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS-RAF-MEK pathway mutations. METHODS: We did a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study at the Royal Marsden National Health Service Foundation Trust (London, UK). Patients were eligible for the study if they were aged 18 years or older, had cancers that were refractory to conventional treatment or for which no conventional therapy existed, and if they had a WHO performance status score of 0 or 1. For the dose-escalation phase, eligible patients had histologically or cytologically confirmed advanced or metastatic solid tumours. For the basket dose-expansion phase, eligible patients had advanced or metastatic solid tumours or multiple myeloma harbouring RAS-RAF-MEK pathway mutations. During the dose-escalation phase, we evaluated three intermittent oral schedules (28-day cycles) in patients with solid tumours: (1) 4·0 mg or 3·2 mg CH5126766 three times per week; (2) 4·0 mg CH5126766 twice per week; and (3) toxicity-guided dose interruption schedule, in which treatment at the recommended phase 2 dose (4·0 mg CH5126766 twice per week) was de-escalated to 3 weeks on followed by 1 week off if patients had prespecified toxic effects (grade 2 or worse diarrhoea, rash, or creatinine phosphokinase elevation). In the basket dose-expansion phase, we evaluated antitumour activity at the recommended phase 2 dose, determined from the dose-escalation phase, in biomarker-selected patients. The primary endpoints were the recommended phase 2 dose at which no more than one out of six patients had a treatment-related dose-limiting toxicity, and the safety and toxicity profile of each dosing schedule. The key secondary endpoint was investigator-assessed response rate in the dose-expansion phase. Patients who received at least one dose of the study drug were evaluable for safety and patients who received one cycle of the study drug and underwent baseline disease assessment were evaluable for response. This trial is registered with ClinicalTrials.gov, NCT02407509. FINDINGS: Between June 5, 2013, and Jan 10, 2019, 58 eligible patients were enrolled to the study: 29 patients with solid tumours were included in the dose-escalation cohort and 29 patients with solid tumours or multiple myeloma were included in the basket dose-expansion cohort (12 non-small-cell lung cancer, five gynaecological malignancy, four colorectal cancer, one melanoma, and seven multiple myeloma). Median follow-up at the time of data cutoff was 2·3 months (IQR 1·6-3·5). Dose-limiting toxicities included grade 3 bilateral retinal pigment epithelial detachment in one patient who received 4·0 mg CH5126766 three times per week, and grade 3 rash (in two patients) and grade 3 creatinine phosphokinase elevation (in one patient) in those who received 3·2 mg CH5126766 three times per week. 4·0 mg CH5126766 twice per week (on Monday and Thursday or Tuesday and Friday) was established as the recommended phase 2 dose. The most common grade 3-4 treatment-related adverse events were rash (11 [19%] patients), creatinine phosphokinase elevation (six [11%]), hypoalbuminaemia (six [11%]), and fatigue (four [7%]). Five (9%) patients had serious treatment-related adverse events. There were no treatment-related deaths. Eight (14%) of 57 patients died during the trial due to disease progression. Seven (27% [95% CI 11·6-47·8]) of 26 response-evaluable patients in the basket expansion achieved objective responses. INTERPRETATION: To our knowledge, this is the first study to show that highly intermittent schedules of a RAF-MEK inhibitor has antitumour activity across various cancers with RAF-RAS-MEK pathway mutations, and that this inhibitor is tolerable. CH5126766 used as a monotherapy and in combination regimens warrants further evaluation. FUNDING: Chugai Pharmaceutical.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Guo C, Chénard-Poirier M, Roda D, et al. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 2020. PMID: 33128873. doi:10.1016/S1470-2045(20)30464-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。